Clinical trials
Liver Inflammation clinical trials
Below are recruiting liver inflammation clinical trials, each written for real people, not researchers. We’re tracking 14 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06802731Recruiting
Testing a tool to measure liver inflammation in NAFLD
This trial studies a device called LivQ-box to see if it can accurately measure liver inflammation in people with nonalcoholic fatty liver disease (NAFLD). It compares the device's results to a liver biopsy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07122700Recruiting
Better tests for fatty liver disease in people with metabolic issues
This study compares new, non-invasive tests to standard liver biopsy for diagnosing fatty liver disease in people with type 2 diabetes or other signs of metabolic syndrome. It aims to see if these simpler tests can replace biopsies.
Miami, FloridaAges 18–75 - NCT06463223Enrolling by invitation
Liver imaging study for children with obesity
This study uses MRI scans to look at the livers of children with obesity, to find early signs of liver problems. It may help doctors understand how to protect the liver in children.
Gothenburg, Västra Götaland CountyAges 9–14 - NCT06212635Recruiting
Bleeding risk in liver cirrhosis and liver cancer
This trial studies bleeding problems in people with advanced liver cirrhosis or liver cancer. It aims to improve understanding of when blood transfusions or treatments are needed.
Stockholm, HuddingeAges 18 years+ - NCT06463366Recruiting
Using MRI to better diagnose liver fat, inflammation, and scarring
This study uses advanced MRI scans to get a clearer picture of liver fat, inflammation, and scarring in people with chronic liver disease. It aims to help doctors diagnose and understand liver problems better.
Shenyang, LiaoningAges 18–75 - NCT02931513Recruiting
Blood marker test in newly diagnosed PBC patients
This study looks at how a specific blood marker (sCD163) changes in people newly diagnosed with primary biliary cholangitis (PBC). It’s mainly meant to see whether this marker could help predict treatment response, especially before starting UDCA.
Aarhus C, Central JutlandAges 18 years+ - NCT07564947Enrolling by invitation
Reishi Mushroom for Fatty Liver Disease
This study tests whether Ganoderma lucidum (reishi mushroom) can improve liver health and reduce inflammation in people with fatty liver disease. Researchers will measure how it affects your liver function and antioxidant levels.
Peshawar, Khyber PakhtunkhwaAges 35–49 - NCT07632677Recruiting
Testing a liver inflammation score in diabetes and fatty liver
This study tests whether a new scoring method can help doctors identify liver inflammation in patients who have both type 2 diabetes and a fatty liver. The goal is to find an easier, safer way to assess liver health without invasive procedures.
Bengbu, AnhuiAges 18 years+ - NCT04838171Recruiting
Study of White Blood Cells in Donors and Patients
This study looks at white blood cells (the body’s immune cells) to learn more about how they behave in health and/or illness. Participation may help researchers understand immune-related changes and support future treatments.
LondonAges Any age - NCT05865691Recruiting
Study blood and organ changes in chronic liver disease
This study looks at how blood clotting, inflammation, and blood vessels change in people with chronic liver disease or cirrhosis. Your blood tests may help researchers understand what drives the disease and could guide future care.
ClichyAges 18 years+ - NCT07329036Recruiting
Liver support therapy for acute liver failure
This trial tests two different blood-filtering treatments for people with severe liver failure who are waiting for or unable to receive a liver transplant. It aims to see how these treatments affect blood clotting, inflammation, and organ function.
PragueAges 18–75 - NCT07476703Recruiting
Extended study on the SCAPIS Stockholm reexamined group
This trial studies data and samples from people already taking part in the main SCAPIS reexamination study in Stockholm. It looks for new findings to help understand heart and lung health.
StockholmAges 56–74 - NCT07093346Recruiting
Pectin supplement for fatty liver disease
This study tests whether a pectin supplement (a fiber found in fruits) can reduce inflammation and improve liver and metabolic health in people with fatty liver disease (MASLD). You might be eligible if you have MASLD, a healthy weight range, and can avoid certain medications and foods.
NottinghamAges 18 years+ - NCT05766449Recruiting
Study of liver inflammation and scarring in hepatitis B or fatty liver
This study looks at what factors predict liver inflammation, scarring (fibrosis), and health outcomes in people with long-term hepatitis B or fatty liver disease. The goal is to better understand who is more likely to worsen over time.
NanjingAges 18 years+
Hear when a new Liver Inflammation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver inflammation?
- Yes. Clin2 currently lists 14 recruiting liver inflammation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver inflammation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver inflammation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.